"The U.S. Food and Drug Administration today expanded the approved use of Imbruvica (ibrutinib) for chronic lymphocytic leukemia (CLL) patients who have received at least one previous therapy.
CLL is a rare blood and bone marrow disease"...
- Patient Information:
Details with Side Effects
Women of childbearing potential should be advised to avoid becoming pregnant while receiving treatment with Dacogen (decitabine injection) and for I month afterwards, and to use effective contraception during this time, [See WARNINGS AND PRECAUTIONS].
Men should be advised not to father a child while receiving treatment with Dacogen (decitabine injection) , and for 2 months afterwards. During these times, men with female partners of childbearing potential should use effective contraception [See WARNINGS AND PRECAUTIONS and Nonclinical Toxicology].
Last reviewed on RxList: 4/1/2010
This monograph has been modified to include the generic and brand name in many instances.
Additional Dacogen Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.